Geneta Science（纳斯达克股票代码：GNTA）股价上涨3.9％

Genenta Science S.p.A. (NASDAQ:GNTA – Get Rating)'s share price shot up 3.9% during trading on Thursday . The company traded as high as $7.08 and last traded at $6.60. 14,480 shares were traded during mid-day trading, an increase of 243% from the average session volume of 4,218 shares. The stock had previously closed at $6.35.

Analyst Ratings Changes

Several analysts have issued reports on the company. EF Hutton Acquisition Co. I started coverage on Genenta Science in a report on Thursday, January 5th. They set a "buy" rating and a $15.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of Genenta Science in a research note on Wednesday, February 8th.

Genenta Science Stock Performance

The company's 50-day moving average price is $6.13 and its 200 day moving average price is $5.47.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Algebris UK Ltd bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA – Get Rating) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 45,000 shares of the company's stock, valued at approximately $242,000. Algebris UK Ltd owned approximately 0.25% of Genenta Science at the end of the most recent quarter. 0.02% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

(Get Rating)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

Further Reading

• Get a free copy of the StockNews.com research report on Genenta Science (GNTA)
• Hormel Hits 2-Year Low, And The Dip Gets Bought
• Here's Why Ross Could Soon Be Hitting All Time Highs
• The Bottom Is In For Salesforce.com
• It's Time For A Fresh Look At The Kroger Co.
• West Fraser's Earnings Scream Timber, Outlook Says Buy

Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.